CTCs

Ask For a Blood test to identify AR-V7 in Circulating Tumor Cells if you are starting Xtandi or Zytiga

One of the hot topics in the prostate cancer community is the value of detecting AR-V7 tumor cells circulating in the blood. AR-V7 tumor cells in the blood predicts response or failure of treatment with enzalutamide (Xtandi) or abiraterone (Zytiga). A recent study found that men who have AR-V7 circulating tumor cells in their blood will not [...]

By Malecare|2017-10-19T10:45:55-04:00December 29th, 2016|abiraterone acetate, Advanced Prostate Cancer, Biomarkers and Prognostic Tools, Chemotherapy, CTCs, Drugs & Treatments, enzalutamide, taxanes, Uncategorized, Xtandi, Zytiga|1 Comment

Better Predicting Advanced Prostate Cancer Outcomes with NaF-PET/CT Scans

Imaging of prostate cancer has been improving by leaps and bounds over the last few years. Current imaging techniques are not sensitive enough to give us an accurate picture of the cancer. This means that we lose predictive abilities and don’t always have adequate information to make the best treatment decisions. It also means, in [...]